Nektar Therapeutics is a biopharmaceutical company that applies polymer chemistry and related drug-delivery science to design new medicines, historically including PEGylation approaches. Its development focus has centered on immunology and immuno-oncology candidates intended to modulate immune responses in cancer and other diseases. Revenue is typically limited and tied to partnerships, royalties or early commercial arrangements rather than a large in-house product franchise. The company serves a research and clinical audience of partners, investigators and specialty physicians.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 11.2 | — | -41.6 | — |
| Q3 2025 | 11.8 | — | -35.5 | — |
| Q4 2025 | 21.8 | — | -36.1 | — |
| Q1 2026 | 10.9 | — | -44.9 | — |
| Q2 2026 | 10.1 | -9.3% | -40.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Lucid Group, Inc. (LCID), Kardigan, Inc. (KARD), G-III Apparel Group, Ltd. (GIII), Seneca Foods Corporation (SENEB), ScanSource, Inc. (SCSC), XPEL, Inc. (XPEL)